-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In the IXORA-R head-to-head trial, patients with moderate to severe plaque psoriasis treated with the interleukin (IL)-17A inhibitor ixekizumab and the IL-23p19 inhibitor guselkumab achieved psoriasis area and 100% improvement of the severity index (PASI 100)
.
Recently, a randomized trial published in Br J Dermatol compared the skin and nail clearance rates after treatment with ixekizumab and guselkumab, as well as patient-reported results
IXORA-R recruited adults with moderate to severe plaque psoriasis, defined as static physician global assessment ≥3, PASI ≥12, and affected body surface area ≥10%
.
Using test Cochran-Mantel-Haenszel performed statistical comparative study, stratified by collection location
statistics
The results showed that 90% of the 1,027 randomly assigned patients completed the trial (465 out of 520 ixekizumab and 459 out of 507 guselkumab)
.
As early as the 2nd to the 16th week, more patients using ixekizumab reached PASI 100 (P <0.
Quality of Life
In summary, the results of this study show that Ixekizumab is not inferior to guselkumab in completely removing skin lesions, and it has an advantage in removing nails at the 24th week
.
Ixekizumab can clear the skin of patients with moderate to severe plaque psoriasis faster, and the cumulative benefit is greater than that of guselkumab
Original source:
A Blauvelt, C Leonardi, et al.
A head-to-head comparison of ixekizumab vs.
guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial in this message
